Acura Pharmaceuticals (ACUR) 10-Q 4 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	786947
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		49,216,817

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$3,821	$774
Marketable securities (Note 6)	10,387	11,322
Accounts receivable, net of allowances of $7 and $5	87	76
Accrued investment income	63	66
Inventories, net (Note 7)	282	304
Prepaid expenses and other current assets	312	471
Other current deferred assets	4	218
Total current assets	14,956	13,231
Property, plant and equipment, net	973	957
Deferred debt issuance costs, net of accumulated amortization of $86 and $69 (Note 9)	145	162
Intangible asset, net of accumulated amortization of $207 and $155 (Note 3)	1,793	1,845
Total assets	17,867	16,195
Current liabilities:
Accounts payable	161	217
Accrued expenses (Note 8)	987	568
Other current liabilities	22	26
Accrued interest	70	70
Sales returns liability	153	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 9)	2,369	1,758
Total current liabilities	3,762	2,992
Long-term debt, net of discount of $283 and $281 (Note 9)	7,348	7,961
Long-term portion of accrued interest	241	190
Total liabilities	11,351	11,143
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 48,947 and 48,848 shares issued and outstanding at 2015 and 2014, respectively	489	488
Additional paid-in capital	367,091	366,898
Accumulated deficit	-361,082	-362,321
Accumulated other comprehensive income (loss)	18	-13
Total stockholders' equity	6,516	5,052
Total liabilities and stockholders' equity	$17,867	$16,195

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Per Share data, unless otherwise specified
Accounts receivable, net of allowances	$7	$5
Accumulated amortization, deferred finance costs	86	69
Finite-lived intangible assets accumulated amortization	207	155
Long-term debt, net of debt discount	$283	$281
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	48,947	48,848
Common stock, shares outstanding	48,947	48,848

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Royalty revenue	$0	$3
Product sales, net	357	39
License fee revenue	5,000	0
Total revenues, net	5,357	42
Operating expenses:
Cost of sales (excluding inventory write-down)	324	38
Inventory write-down (Note 7)	260	133
Research and development	964	1,438
Selling, marketing, general and administrative	2,297	2,259
Total operating expenses	3,845	3,868
Operating income (loss)	1,512	-3,826
Non-Operating income (expense):
Investment income	35	44
Loss on sales of marketable securities	0	-5
Interest expense (Note 9)	-308	-301
Total other expense, net	-273	-262
Income (loss) before income taxes	1,239	-4,088
Provision for income taxes	0	0
Net income (loss)	1,239	-4,088
Other comprehensive income:
Unrealized gains on securities	31	29
Total other comprehensive income	31	29
Comprehensive income (loss)	$1,270	($4,059)
Income (loss) per share:
Basic	$0.03	($0.08)
Diluted	$0.03	($0.08)
Weighted average shares outstanding:
Basic	48,965	48,842
Diluted	49,347	48,842

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
In Thousands
Beginning Balance at Dec. 31, 2014	$5,052	$488	$366,898	($362,321)	($13)
Beginning Balance (in shares) at Dec. 31, 2014		48,848
Net income	1,239	0	0	1,239	0
Other comprehensive income	31	0	0	0	31
Share-based compensation	160	0	160	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		99
Net distribution of common stock pursuant to restricted stock unit award plan	1	1	0	0	0
Modification to warrants issued with promissory notes	33	0	33	0	0
Ending Balance at Mar. 31, 2015	$6,516	$489	$367,091	($361,082)	$18
Ending Balance (in shares) at Mar. 31, 2015		48,947

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flows from Operating Activities:
Net income (loss)	$1,239	($4,088)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation	30	28
Provision to reduce inventory to net realizable value	260	133
Provision for sales returns	153	0
Share-based compensation	160	198
Amortization of debt discount and deferred debt issue costs	48	46
Amortization of bond premium in marketable securities	41	76
Amortization of intangible asset	52	0
Loss on sales of marketable securities	0	5
Changes in assets and liabilities:
Accounts receivable	-11	89
Accrued investment income	3	18
Inventories	-238	24
Prepaid expenses and other current assets	159	-89
Other current deferred assets	214	1
Other assets	0	-2
Accounts payable	-56	219
Accrued expenses	419	313
Deferred revenue	-353	3
Accrued interest - current and long term	51	46
Other current liabilities	-4	0
Net cash provided by (used in) operating activities	2,167	-2,980
Cash Flows from Investing Activities:
Purchases of marketable securities	0	-1,110
Proceeds from sale and maturities of marketable securities	925	1,170
Additions to property, plant and equipment	-46	-34
Net cash provided by investing activities	879	26
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	-529
Net cash provided by (used in) financing activities	1	-520
Net increase (decrease) in cash and cash equivalents	3,047	-3,474
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	3,821	8,866
Cash paid during the year for:
Interest	209	209
Income taxes	$0	$0

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Supplemental Disclosure of Noncash Financing Activities:
Common stock withheld in exercise costs in shares
Class of Warrant or Right, Outstanding	298,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50
Additions To Debt Instrument Unamortized Discount	$33
Maximum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.60
Minimum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50
Stock options
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		24,000
Common stock withheld in exercise costs in shares		16,000
Common stock withheld in exercise costs		32
Withholding of exercise cost in shares		2,000
Minimum statutory withholding payroll taxes withheld		4
Common Stock issued upon exercise		6,000
Restricted Stock Unit
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		829,000
Common stock withheld in exercise costs in shares		4,000
Common stock withheld in exercise costs		7
Withholding of exercise cost in shares		315,000
Minimum statutory withholding payroll taxes withheld		$525
Common Stock issued upon exercise		510,000

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2015
Description Of Business Disclosure [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS
	Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo™ Tablets (formerly known as Oxecta®) (oxycodone HCl, CII), is the first approved product utilizing Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. We are advised that Egalet plans to launch Oxaydo in the United States in the third quarter of 2015. We have also developed Impede® Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. In August 2014, we were awarded a grant from the National Institute on Drug Abuse to advance early stage development of our third abuse deterrent technology, Limitx™. Limitx is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.

ACCOUNTING_PRONOUNCEMENTS

ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
ACCOUNTING PRONOUNCEMENTS	NOTE 2 – ACCOUNTING PRONOUNCEMENTS
	Revenue from Contracts with Customers
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).  We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018.
	Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, which will explicitly require management to assess an entity’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Currently, there is no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for the first annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of adopting this update on its financial statements.
	Presentation of Debt Issue Costs
	In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. Early adoption of the amendments is permitted for financial statements that have not been previously issued. The Company is currently evaluating the impact of the adoption of ASU 2015-03 on the Company's consolidated financial statements.

LICENSE_DEVELOPMENT_AND_COMMER

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS	3 Months Ended
	Mar. 31, 2015
Research and Development Disclosure [Abstract]
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT	NOTE 3 - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS
	Pfizer Agreement
	In October 2007, we entered into a License, Development and Commercialization Agreement, or the Pfizer Agreement, with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer, to develop and commercialize in the United States, Canada and Mexico certain opioid analgesic products utilizing our Aversion Technology. Aversion Oxycodone was approved by the U.S. Food and Drug Administration, or FDA, on June 17, 2011 and sales of Aversion Oxycodone, under Pfizer’s brand name Oxecta, commenced in February 2012. For sales of Aversion Oxycodone occurring on and following February 2, 2013 (the one year anniversary of first commercial sale), Pfizer paid us a royalty of 5% of net sales of Aversion Oxycodone.
	On September 24, 2012, we entered into a letter agreement with Pfizer which provided for the termination of Pfizer’s license to our Aversion Technology used in three development-stage products licensed to Pfizer and for the return of these products to us. On April 9, 2014, we entered into a second letter agreement with Pfizer providing for the termination of the Pfizer Agreement and the return of Aversion Oxycodone to us effective April 9, 2014 in exchange for a one-time termination payment of $2.0 million. Pfizer’s royalty payment obligations relating to Aversion Oxycodone ceased effective April 9, 2014 and all royalty payments due to us have been received. Our termination payment of $2.0 million has been recorded on our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent for Aversion Oxycodone. The recorded value of the intangible asset will be periodically assessed for impairment. We also purchased from Pfizer selected raw and packaging material inventories for $260 thousand relating to the Aversion Oxycodone product. During the quarter ended March 31, 2015, we recorded a 100% reserve against these inventories which is reflected in operating expense.
	Egalet Agreement
	On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo™. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we are transferring the approved NDA for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States.
	In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.
	Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016, but in no event earlier than June 30, 2015. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We will receive from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo. Royalties will be reduced upon the entry of generic equivalents, as well for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.
	The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.
	Paragraph IV ANDA Litigation
	On or about September 17, 2012, we believe the FDA internally changed the status of Oxaydo (formerly known as Oxecta®) to be considered a Reference Listed Drug, or RLD. An RLD is the standard to which all generic versions must be shown to be bioequivalent and a drug company seeking approval to market a generic equivalent must refer to the RLD. By designating Oxaydo as an RLD, the FDA was allowed to accept ANDAs referencing Oxaydo.
	On September 20, 2012, we announced that we had received a Paragraph IV Certification Notice under 21 U.S.C. 355(j) (a Paragraph IV Notice) from a generic sponsor of an ANDA for a generic drug listing Oxaydo as the reference listed drug. Since such date, we have received similar Paragraph IV Notices from four other generic pharmaceutical companies that have filed ANDAs listing Oxaydo as the reference drug. The Paragraph IV Notices refer to our U.S. Patent Numbers 7,201,920, 7,510,726 and 7,981,439, which cover our Aversion® Technology and Oxaydo. The Paragraph IV Notices state that each generic sponsor believes that such patents are invalid, unenforceable or not infringed. On October 31, 2012, we initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc. and Sandoz Inc., and on April 29, 2013 we initiated suit against Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book. In January 2013, we dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry.
	On October 9, 2013, we announced that we had entered into distinct Settlement Agreements with each of Par and Impax, to settle our patent infringement action pending against them in the United States District Court for the District of Delaware. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations.
	Under the terms of the Settlement Agreement with Par, Par may launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxaydo product.
	Under the Settlement Agreement with Impax, Impax may launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo® product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo® product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax would become effective prior to such time.
	On May 8, 2014, we announced that we had entered into a Settlement Agreement with Ranbaxy Inc. to settle our patent infringement action pending in the United States District Court for the District of Delaware. The Settlement Agreement provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product.
	On May 21, 2014, we announced that we had entered into a Settlement Agreement with Sandoz Inc. to settle our patent infringement action pending against Sandoz in the United States District Court for the District of Delaware. Under the Settlement Agreement, Sandoz may launch its generic to the Oxaydo product in the U.S., through the grant of a non-exclusive license from us that would trigger 180 days following the first sale of a generic to the Oxaydo product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic to the Oxaydo product is first sold in the U.S). In certain circumstances, our license to Sandoz would become effective prior to such time. Sandoz is not obligated to pay us a royalty if its current formulation of its generic to the Oxaydo product is approved by the FDA. In the event Sandoz changes or modifies the structure of its generic Oxaydo product, or materially changes or modifies the amounts or type of any excipient used in the Sandoz formulation disclosed in its ANDA filing with the FDA as of July 30, 2013, Sandoz is required to pay us a royalty based upon the Net Profits (as defined in the Settlement Agreement) derived from the net sales of such changed or modified Sandoz generic Oxaydo product in the United States.
	Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

REVENUE_RECOGNITION

REVENUE RECOGNITION	3 Months Ended
	Mar. 31, 2015
Revenue Recognition [Abstract]
REVENUE RECOGNITION	NOTE 4 - REVENUE RECOGNITION
	Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. We record revenue from our Nexafed product sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated.
	Nexafed was launched in mid-December 2012. We sell Nexafed in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Nexafed is sold subject to the right of return for a period of up to twelve months after the product expiration. Nexafed currently has a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of Nexafed, we could not reliably estimate expected returns of the product at the time of shipment to certain customers and accordingly we had deferred revenue. During the first quarter ended March 31, 2015 we determined we had obtained sufficient sales returns history to reasonably estimate future returns. As a result of this change, we recorded a one-time adjustment in the first quarter ended March 31, 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $314 thousand after recording an allowance for sales returns of $120 thousand, and cost of sales of $255 thousand. At March 31, 2015 we have a $153 thousand sales returns liability which will be reviewed against sales returns activity each quarter. Revenue will be recognized at the time the product is sold to a customer.
	Commencing in February 2013, we began earning royalties based on net sales of Aversion Oxycodone by Pfizer. We earned royalties of approximately $3 thousand for the three months ended March 31, 2014. The Pfizer Agreement was terminated effective April 9, 2014 and Pfizer’s royalty payment obligations ceased as of such date. All royalties owed to us have been received.
	Shipping and Handling Costs
	We record shipping and handling costs in selling expenses. The amounts recorded to selling expenses from the shipments of Nexafed during each of the three month periods ended March 31, 2015 and 2014 were not material.

RESEARCH_AND_DEVELOPMENT_ACTIV

RESEARCH AND DEVELOPMENT ACTIVITIES	3 Months Ended
	Mar. 31, 2015
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT ACTIVITIES	NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES
	Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have any accrued CRO costs and clinical trial study expenses at either March 31, 2015 or December 31, 2014. We did not have any prepaid CRO costs and clinical trial study expenses at either March 31, 2015 or December 31, 2014.

INVESTMENTS_IN_MARKETABLE_SECU

INVESTMENTS IN MARKETABLE SECURITIES	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS IN MARKETABLE SECURITIES	NOTE 6 - INVESTMENTS IN MARKETABLE SECURITIES
	Investments in marketable securities consisted of the following:
		March 31, 2015		December 31, 2014
		(in millions)		(in millions)
	Marketable securities:
	Corporate bonds - maturing within 1 year	$	2.8	$	3.5
	Corporate bonds - maturing after 1 year and through March 2017		2.6		2.8
	Exchange-traded funds		5		5
	Total marketable securities	$	10.4	$	11.3
	The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our investments are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs.
	The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities:
		March 31, 2015
		(in millions)
		Cost		Gross		Gross		Fair
				Unrealized		Unrealized		Value
				Gains		Losses
	Available-for-sale:
	Corporate bonds	$	5.4	$	-	$	-	$	5.4
	Exchange-traded funds		5		-		-		5
	Total - Current	$	10.4	$	-	$	-	$	10.4
		December 31, 2014
		(in millions)
		Cost		Gross		Gross		Fair
				Unrealized		Unrealized		Value
				Gains		Losses
	Available-for-sale:
	Corporate bonds	$	6.3	$	-	$	-	$	6.3
	Exchange-traded funds		5		-		-		5
	Total - Current	$	11.3	$	-	$	-	$	11.3
	Fair Value Measurement
	Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement.
	Our assets measured at fair value or disclosed at fair value on a recurring basis as at March 31, 2015 and December 31, 2014 consisted of the following:
		March 31, 2015
		(in millions)
		Total		Level 1		Level 2		Level 3
	Assets:
	Corporate bonds		5.4		-		5.4		-
	Exchange-traded funds		5		5		-		-
	Total	$	10.4	$	5	$	5.4	$	-
		December 31, 2014
		(in millions)
		Total		Level 1		Level 2		Level 3
	Assets:
	Corporate bonds		6.3		-		6.3		-
	Exchange-traded funds		5	$	5	$	-	$	-
	Total	$	11.3		5		6.3		-
	Accumulated Other Comprehensive Income (Loss)
	Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at March 31, 2015 consisted of unrealized gains on securities of $18 thousand. Accumulated other comprehensive income (loss) at December 31, 2014 consisted of unrealized losses on securities of $13 thousand.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 7 – INVENTORIES
	Inventories consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed product. During 2014, we purchased raw and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. During the quarter ended March 31, 2015, we recorded a $260 thousand reserve against the raw and packaging material inventory on our Aversion Oxycodone product as our license partner will secure their own material requirements. During the quarter ended March 31, 2014, we increased our inventory reserves by $133 thousand against finished goods.
	We have recorded Nexafed deferred revenue of $0.35 million at December 31, 2014. The related cost of sales of $0.22 million at December 31, 2014 is reported in our balance sheet in the other current deferred assets account and excluded from the reported year end inventories. We will recognize both the revenue and cost of sales on these Nexafed shipments once the right of return no longer exists or adequate history and information becomes available to estimate sales returns. During the first quarter ended March 31, 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future returns. As a result of this change, we recorded a one-time adjustment in the first quarter ended March 31, 2015 to recognize revenue that had previously been deferred, resulting in additional net revenue of $314 thousand and cost of sales of $255 thousand. Revenue will be recognized at the time the product is sold to a customer.
	Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.
	Inventories are summarized as follows:
		March 31,		December 31,
		2015		2014
		(in thousands)
	Raw and packaging materials	$	260	$	260
	Finished goods		282		44
	Total		542		304
	Less: reserve for raw materials		-260		(-)
	Net	$	282	$	304

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 8 - ACCRUED EXPENSES
	Accrued expenses are summarized as follows:
		March 31,		December 31,
		2015		2014
		(in thousands)
	Payroll, payroll taxes, and benefits	$	146	$	94
	Professional services		195		253
	Franchise taxes		17		13
	Property taxes		17		15
	Marketing and promotion		251		61
	Clinical, non-clinical and regulatory services		241		83
	Other fees and services		120		49
	Total	$	987	$	568

DEBT

DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
DEBT	NOTE 9 – DEBT
	On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The full principal amount of the Term Loan was funded on December 27, 2013. We are using the proceeds of the Loan Agreement for general working capital and to fund our business requirements. The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company is required to make monthly interest-only payments until the April 1, 2015 (“Amortization Date”) and starting on the Amortization Date, the Company is required to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the Loan Agreement, the Company granted Lender a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 298 thousand shares of our common stock at an exercise price equal to $1.595 per share (the “Warrants”). We recorded $400 thousand as debt discount associated with the fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.
	On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the warrant previously issued to the Lender to purchase 298 thousand shares of our Common Stock was lowered from $1.595 to $0.504 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment) and we recorded additional debt discount of $33 representing the fair value of the warrant modification, (ii) we agreed to maintain a $2.5 million cash reserve until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.
	The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 2% of the principal prepaid, if prepaid prior to December 27, 2015, and 1% of the principal prepaid if prepaid after December 27, 2015. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We will incur and accrue additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate.
	The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate.
	The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.
	Our debt at March 31, 2015 is summarized below (in thousands):
	Debt	Current		Long-term		Total
	Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
	Principal payments		-		-		-
	Classification		611		-611		-
	Balance at Mar 31, 2015	$	2,369	$	7,631	$	10,000
	Debt Discount	Current		Long-term		Total
	Balance at Dec 31, 2014	$	-	$	-281	$	-281
	Additions		-		-33		-33
	Amortization expense		-		31		31
	Balance at Mar 31, 2015	$	-	$	-283	$	-283
	Debt, net	$	2,369	$	7,348	$	9,717
	Our interest expense during the three month ended March 31, 2015 and 2014 consisted of the following:
		Three months Ended
		March 31,
		2015		2014
		(in thousands)
	Interest expense:
	Secured Promissory notes	$	260	$	254
	Debt discount		31		30
	Debt issue costs		17		17
	Total interest expense	$	308	$	301
	The annual principal payments of the debt at March 31, 2015 are as follows:
		Annual
		Principal Payments
		(in thousands)
	2015	$	1,758
	2016		2,522
	2017		2,741
	2018		2,979
	Total	$	10,000

EQUITY_FINANCING

EQUITY FINANCING	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
EQUITY FINANCING	NOTE 10 – EQUITY FINANCING
	Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we may sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $13 million. We did not sell any shares of our common stock pursuant to our prospectus supplement during the three month period ended March 31, 2015 or during the year ended December 31, 2014. As of March 31, 2015, we may sell shares of our common stock under the S-3 registration statement having gross sales proceeds of up to $7.9 million. Net proceeds of these transactions may be used for general corporate purposes, including working capital, capital expenditures, research, development and marketing expenditures and clinical trial expenditures.

COMMON_STOCK_WARRANTS

COMMON STOCK WARRANTS	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
COMMON STOCK WARRANTS	NOTE 11 - COMMON STOCK WARRANTS
	We have outstanding common stock purchase warrants (“warrants”) exercisable for 298 thousand shares of our common stock having an exercise price of $0.504 per share with an expiration date in December 2020. In January 2015, the exercise price of these warrants was reduced from $1.595 to $0.504 per share. (see Note 9). These warrants contain a cashless exercise feature. Our common stock warrant activity during the three months ended March 31, 2015 and 2014 is shown below:
		Three months Ended
		March 31,
		2015			2014
		Number	Weighted		Number	Weighted
		(000’s)	Average		(000’s)	Average
			Exercise			Exercise
			Price			Price
	Outstanding, beginning	298	$	1.6	2,154	$	3.15
	Issued	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Outstanding, ending	298	$	0.5	2,154	$	3.15

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 12 - SHARE-BASED COMPENSATION
	Share-based Compensation
	We have three share-based compensation plans covering stock options and RSUs for our employees and directors.
	We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the fair-value method. The fair value of the RSUs is the market price of our common stock on the date of grant, less its exercise cost.
	Our share-based compensation expense recognized in the Company’s results of operations comprised the following:
			Three Months Ended
			March 31,
			2015		2014
	Research and development expense:
	Restricted stock units		$	39	$	57
	General and administrative expense:
	Stock options			98		141
	Restricted stock units			23		-
	Subtotal			121		141
	Total		$	160	$	198
	Stock Option Award Plans
	We have one stock option plan in effect, and one stock option plan has expired by its terms, but pursuant to which stock options have been granted and remain outstanding. Our stock option award activity during the three months ended March 31, 2015 and 2014 is shown below:
		Three months Ended
		March 31,
			2015				2014
			Number		Weighted		Number of		Weighted
			of		Average		Options		Average
			Options		Exercise		(000’s)		Exercise
			(000’s)		Price				Price
	Outstanding, beginning			4,556	$	4.14		3,738	$	4.99
	Granted			-		-		-		-
	Exercised			-		-		-31		1.3
	Forfeited or expired			-75		5.25		-		-
	Outstanding, ending			4,481	$	4.13		3,707	$	5.02
	Options exercisable			3,573	$	5		3,189	$	5.54
	During the three months ended March 31, 2014, a total of 31 thousand stock options were exercised by our employees. Of the total amount of stock option exercises, 24 thousand of stock options were exercised under various cashless exercise features of the plan. Our employees elected to have 18 thousand shares withheld in satisfaction of $36 thousand for both the exercise costs and withholding tax obligations on those options, resulting in the net issuance of 13 thousand shares of common stock from all stock option exercises.
	Restricted Stock Unit Award Plans
	We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.
	A summary of the grants under the RSU Plans consisted of the following:
			Three months Ended March 31,
			2015				2014
			(in thousands)
			Number of		Number of		Number of		Number of
			RSUs		Vested		RSUs		Vested
					RSUs				RSUs
	Outstanding, beginning			147		147		829		829
	Granted			206		-		-		-
	Distributed			-129		-129		-829		-829
	Vested			-		52		-		-
	Forfeited or expired			-		-		-		-
	Outstanding, ending			224		70		-		-
	2005 Restricted Stock Unit Award Plan
	Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014. On January 1, 2014, 0.50 million shares were distributed to the holders while 0.33 million shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.5 million withholding tax obligations.
	All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014.
	2014 Restricted Stock Unit Award Plan
	Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 2.0 million shares of our common stock pursuant to awards under the 2014 RSU Plan. As of March 31, 2015, 1.65 million shares are available for award under the 2014 RSU Plan.
	Information about the RSU grants under the 2014 RSU Plan is as follows:
		·	On May 1, 2014, we awarded approximately 37 thousand RSUs to each of our 4 non-employee directors. Such RSU awards vested 50% on June 30, 2014 and 25% on each of September 30 and December 31, 2014. Such non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet. The liability was $26 thousand at December 31, 2014. Accordingly the vested portion of the awards containing the cash settlement feature are being marked-to-market each reporting period until they are distributed. Marked-to-market accounting can create fluctuations in our compensation expense including the need to record additional expense. RSU awards are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.
		·	On January 2, 2015, we awarded approximately 51.5 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting and the liability recorded in the Company’s balance sheet was $22 thousand at March 31, 2015. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards will be distributed on January 4, 2016.
	Information about the distribution of shares under the 2014 RSU Plan is as follows:
		·	On January 2, 2015, 129 thousand RSUs from the May 1, 2014 award were distributed and 18 thousand RSUs were deferred until a future distribution date. Of the 129 thousand RSUs distributed, 99 thousand RSUs were distributed in common stock and 30 thousand RSUs were settled in cash.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES
	We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both March 31, 2015 and December 31, 2014, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss (“NOL”) carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. We have approximately $51.5 million federal income tax benefits at December 31, 2014 derived from $151.4 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.9 million state NOLs, available to offset future taxable income, some of which have limitations for use as prescribed under IRC Section 382. Our Federal and state NOLs will expire in varying amounts between 2016 and 2034 if not used, and those expirations will cause fluctuations in our valuation allowances. As of December 31, 2014 we had federal research and development tax credits of approximately $1.1 million, which expire in the years 2024 through 2034. We also had approximately $0.3 million of Indiana state research and development tax credits, which expire in the years 2015 through 2017.

EARNINGS_PER_SHARE_EPS

EARNINGS PER SHARE ("EPS")	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE ("EPS")	NOTE 14 – EARNINGS PER SHARE (“EPS”)
	Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 12). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2014 as the Company reported a net loss for the three month period, and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. The Weighted-average common shares outstanding (diluted) computation is not impacted during any period where the exercise price of a stock option is greater than the average market price. There were 3.58 million non-dilutive equity awards outstanding for the three-months ended March 31, 2015 that are not included in the corresponding period Weighted-average common shares outstanding (diluted) computation.
	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:
		Three months Ended March 31,
		2015		2014
		(in thousands except per share
		data)
	EPS - basic
	Numerator: net income (loss)	$	1,239	$	-4,088
	Denominator:
	Common shares		48,947		48,842
	Vested RSUs		18		-
	Basic weighted average shares outstanding		48,965		48,842
	EPS - basic	$	0.03	$	-0.08
	EPS – assuming dilution
	Numerator: net income (loss)	$	1,239	$	-4,088
	Denominator:
	Common shares		48,947		48,842
	Vested RSUs		170		-
	Stock options		167		-
	Common stock warrants		63		-
	Diluted weighted average shares outstanding		49,347		48,842
	EPS - diluted	$	0.03	$	-0.08
	Excluded dilutive securities:
	Common stock issuable:
	Stock options		3,580		3,707
	Common stock warrants		-		2,154
	Total excluded potentially dilutive shares		3,580		5,861

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES
	Purdue Pharma Complaint
	In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. patent 8,389,007. The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. We deny the allegations in the complaint, believe they are without merit and intend to defend the action vigorously.
	Reglan®/Metoclopramide Litigation
	Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including us, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.
	In the Pennsylvania action, over 200 lawsuits have been filed against us and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 99 pending cases against us, with more than 400 individual plaintiffs.
	In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 19 years ago.  In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases. We have consistently maintained the position that these claims are without merit and intend to vigorously defend these actions.
	In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. As of September 2012, the New Jersey trial court dismissed Acura with prejudice.  In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing decision.
	In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions. On appeal, the Pennsylvania Superior Court held in a July 29, 2013 decision that federal preemption applied, but that Mensing did not completely bar all claims and refused to dismiss these cases. On September 17, 2014, the Pennsylvania Supreme Court declined to hear a further appeal. On December 16, 2014, Generic Defendants filed a Petition for a Writ of Certiorari requesting that the United States Supreme Court agree to hear a further appeal on the grounds that federal preemption under Mensing should completely bar all of these claims. The Court is expected to issue its decision concerning acceptance or denial of this appeal by June 30, 2015. All trial court proceedings have been stayed pending resolution of this lengthy appeal process.  To the extent that plaintiffs intend to pursue their claims in the future, if the appeal is denied, Acura nonetheless remains optimistic that most, if not all, of these Philadelphia cases will eventually be dismissed against us based upon the favorable aspects of the Superior Court’s narrow preemption ruling and lack of product identification, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.
	In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generics Defendants’ appeals from this order were denied by the California appellate courts.  Therefore, subject to further developments, plaintiffs may be permitted to proceed with these lawsuits including state law claims based on (1) failing to communicate warnings to physicians through “Dear Doctor” letters; and (2) failure to update labeling to adopt brand labeling changes. California trial court also has acknowledged the preemptive effect of Mensing so that any claim “that would render the generic defendants in violation of federal law if they are found responsible under a state law cause of action, would not be permissible.”
	In May 2014, the California Superior Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett decision.  More recently, on April 10, 2015, Judge Kramer ruled in plaintiffs’ favor on a jurisdictional waiver motion against PLIVA and Teva which could be applied in the future to other defendants. Thus far, Generic Defendants (including Acura) have not been required to file answers or other responsive pleadings in each individual case in which they are named defendants. Within the next few months, these cases also will be transferred to a new judge who will address a case management schedule for claims against Generic Defendants and possible selection of bellwether cases for focused discovery and trial. To date, however, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by us.  Therefore, we expect the number of plaintiffs with possible claims to be reduced voluntarily or by motion practice.  Action will be taken in an effort to dismiss Acura from these cases, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.
	As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of March 31, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.
	Facility Lease
	The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2016 for approximately $25 thousand annually.

INVESTMENTS_IN_MARKETABLE_SECU1

INVESTMENTS IN MARKETABLE SECURITIES (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Investments in marketable securities consisted of the following:
		March 31, 2015		December 31, 2014
		(in millions)		(in millions)
	Marketable securities:
	Corporate bonds - maturing within 1 year	$	2.8	$	3.5
	Corporate bonds - maturing after 1 year and through March 2017		2.6		2.8
	Exchange-traded funds		5		5
	Total marketable securities	$	10.4	$	11.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities:
		March 31, 2015
		(in millions)
		Cost		Gross		Gross		Fair
				Unrealized		Unrealized		Value
				Gains		Losses
	Available-for-sale:
	Corporate bonds	$	5.4	$	-	$	-	$	5.4
	Exchange-traded funds		5		-		-		5
	Total - Current	$	10.4	$	-	$	-	$	10.4
		December 31, 2014
		(in millions)
		Cost		Gross		Gross		Fair
				Unrealized		Unrealized		Value
				Gains		Losses
	Available-for-sale:
	Corporate bonds	$	6.3	$	-	$	-	$	6.3
	Exchange-traded funds		5		-		-		5
	Total - Current	$	11.3	$	-	$	-	$	11.3
Fair Value, Assets Measured on Recurring Basis	Our assets measured at fair value or disclosed at fair value on a recurring basis as at March 31, 2015 and December 31, 2014 consisted of the following:
		March 31, 2015
		(in millions)
		Total		Level 1		Level 2		Level 3
	Assets:
	Corporate bonds		5.4		-		5.4		-
	Exchange-traded funds		5		5		-		-
	Total	$	10.4	$	5	$	5.4	$	-
		December 31, 2014
		(in millions)
		Total		Level 1		Level 2		Level 3
	Assets:
	Corporate bonds		6.3		-		6.3		-
	Exchange-traded funds		5	$	5	$	-	$	-
	Total	$	11.3		5		6.3		-

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	Inventories are summarized as follows:
		March 31,		December 31,
		2015		2014
		(in thousands)
	Raw and packaging materials	$	260	$	260
	Finished goods		282		44
	Total		542		304
	Less: reserve for raw materials		-260		(-)
	Net	$	282	$	304

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	Accrued expenses are summarized as follows:
		March 31,		December 31,
		2015		2014
		(in thousands)
	Payroll, payroll taxes, and benefits	$	146	$	94
	Professional services		195		253
	Franchise taxes		17		13
	Property taxes		17		15
	Marketing and promotion		251		61
	Clinical, non-clinical and regulatory services		241		83
	Other fees and services		120		49
	Total	$	987	$	568

DEBT_Tables

DEBT (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Our debt at March 31, 2015 is summarized below (in thousands):
	Debt	Current		Long-term		Total
	Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
	Principal payments		-		-		-
	Classification		611		-611		-
	Balance at Mar 31, 2015	$	2,369	$	7,631	$	10,000
	Debt Discount	Current		Long-term		Total
	Balance at Dec 31, 2014	$	-	$	-281	$	-281
	Additions		-		-33		-33
	Amortization expense		-		31		31
	Balance at Mar 31, 2015	$	-	$	-283	$	-283
	Debt, net	$	2,369	$	7,348	$	9,717
Schedule of Interest Expense	Our interest expense during the three month ended March 31, 2015 and 2014 consisted of the following:
		Three months Ended
		March 31,
		2015		2014
		(in thousands)
	Interest expense:
	Secured Promissory notes	$	260	$	254
	Debt discount		31		30
	Debt issue costs		17		17
	Total interest expense	$	308	$	301
Schedule Of Long Term Debt Future Principal Payments Year	The annual principal payments of the debt at March 31, 2015 are as follows:
		Annual
		Principal Payments
		(in thousands)
	2015	$	1,758
	2016		2,522
	2017		2,741
	2018		2,979
	Total	$	10,000

COMMON_STOCK_WARRANTS_Tables

COMMON STOCK WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
COMMON STOCK WARRANTS	Our common stock warrant activity during the three months ended March 31, 2015 and 2014 is shown below:
		Three months Ended
		March 31,
		2015			2014
		Number	Weighted		Number	Weighted
		(000’s)	Average		(000’s)	Average
			Exercise			Exercise
			Price			Price
	Outstanding, beginning	298	$	1.6	2,154	$	3.15
	Issued	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Outstanding, ending	298	$	0.5	2,154	$	3.15

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Our share-based compensation expense recognized in the Company’s results of operations comprised the following:
			Three Months Ended
			March 31,
			2015		2014
	Research and development expense:
	Restricted stock units		$	39	$	57
	General and administrative expense:
	Stock options			98		141
	Restricted stock units			23		-
	Subtotal			121		141
	Total		$	160	$	198
Schedule of Share-based Compensation, Stock Options, Activity	Our stock option award activity during the three months ended March 31, 2015 and 2014 is shown below:
		Three months Ended
		March 31,
			2015				2014
			Number		Weighted		Number of		Weighted
			of		Average		Options		Average
			Options		Exercise		(000’s)		Exercise
			(000’s)		Price				Price
	Outstanding, beginning			4,556	$	4.14		3,738	$	4.99
	Granted			-		-		-		-
	Exercised			-		-		-31		1.3
	Forfeited or expired			-75		5.25		-		-
	Outstanding, ending			4,481	$	4.13		3,707	$	5.02
	Options exercisable			3,573	$	5		3,189	$	5.54
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of the grants under the RSU Plans consisted of the following:
			Three months Ended March 31,
			2015				2014
			(in thousands)
			Number of		Number of		Number of		Number of
			RSUs		Vested		RSUs		Vested
					RSUs				RSUs
	Outstanding, beginning			147		147		829		829
	Granted			206		-		-		-
	Distributed			-129		-129		-829		-829
	Vested			-		52		-		-
	Forfeited or expired			-		-		-		-
	Outstanding, ending			224		70		-		-

EARNINGS_PER_SHARE_EPS_Tables

EARNINGS PER SHARE ("EPS") (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:
		Three months Ended March 31,
		2015		2014
		(in thousands except per share
		data)
	EPS - basic
	Numerator: net income (loss)	$	1,239	$	-4,088
	Denominator:
	Common shares		48,947		48,842
	Vested RSUs		18		-
	Basic weighted average shares outstanding		48,965		48,842
	EPS - basic	$	0.03	$	-0.08
	EPS – assuming dilution
	Numerator: net income (loss)	$	1,239	$	-4,088
	Denominator:
	Common shares		48,947		48,842
	Vested RSUs		170		-
	Stock options		167		-
	Common stock warrants		63		-
	Diluted weighted average shares outstanding		49,347		48,842
	EPS - diluted	$	0.03	$	-0.08
	Excluded dilutive securities:
	Common stock issuable:
	Stock options		3,580		3,707
	Common stock warrants		-		2,154
	Total excluded potentially dilutive shares		3,580		5,861

Recovered_Sheet1

License, Development, and Commercialization Agreements - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
License Development and Commercialization Agreement [Line Items]
Inventory, Raw Materials and Supplies, Gross	260,000
Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Patents expiration year	expire between November 2023 and March 2025
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Percentage of royalty	5.00%
Payment for Termination	2,000,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Line of Credit Facility, Description	Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016, but in no event earlier than June 30, 2015
Minimum Net Sales Reaching Description	one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year
Agreement Termination Notice Description	Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo
Minimum | Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty	10.00%
Maximum | Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty	15.00%

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Sales Inducements, Additions	$255,000	$0
Royalty Revenue, Total	0	3,000
Deferred Revenue, Revenue Recognized	314,000
Sales Returns Liability	153,000
Allowance for Sales Returns [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales Returns and Allowances, Goods	120,000
Pfizer [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty Revenue, Total		$3,000

Recovered_Sheet2

Research and Development Activities - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Research And Development Expense Current	$0	$0
Prepaid Research And Development Expense Current	$0	$0

Summary_of_Investments_in_Mark

Summary of Investments in Marketable Securities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Marketable securities:
Corporate bonds - maturing within 1 year	$2.80	$3.50
Corporate bonds - maturing after 1 year and through March 2017	2.6	2.8
Total marketable securities	10.4	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$5	$5

Available_for_Sale_Securities_

Available for Sale Securities Continuous Unrealized Loss Position Fair Value (Detail) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	$10.40	$11.30
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	10.4	11.3
Corporate Bonds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	5.4	6.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	5.4	6.3
Exchange-traded funds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	5	5
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$5	$5

Assets_Measured_at_Fair_Value_

Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Assets:
Total marketable securities	$10.40	$11.30
Corporate bonds
Assets:
Total marketable securities	5.4	6.3
Exchange-traded funds
Assets:
Total marketable securities	5	5
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	5	5
Fair Value, Inputs, Level 1 | Corporate bonds
Assets:
Total marketable securities		0
Fair Value, Inputs, Level 1 | Exchange-traded funds
Assets:
Total marketable securities	5	5
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	5.4	6.3
Fair Value, Inputs, Level 2 | Corporate bonds
Assets:
Total marketable securities	5.4	6.3
Fair Value, Inputs, Level 2 | Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 | Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 | Exchange-traded funds
Assets:
Total marketable securities	$0	$0

Recovered_Sheet3

Investments In Marketable Securities - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Investment In Marketable Securities [Line Items]
Unrealized gains on securities	$31	$29	$13

Schedule_of_Inventories_Detail

Schedule of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]
Raw and packaging materials	$260	$260
Finished goods	282	44
Total	542	304
Less: reserve for raw materials	-260	0
Net	$282	$304

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	$260	$260
Inventory Reserve For Raw Materials	260	0
Cost of Goods Sold	255	220
Deferred Revenue, Current	0	353
Deferred Revenue, Revenue Recognized	314
Inventory Reserve For Finished Goods			$133

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Line Items]
Payroll, payroll taxes, and benefits	$146	$94
Professional services	195	253
Franchise taxes	17	13
Property taxes	17	15
Marketing and Promotion	251	61
Clinical, non-clinical and regulatory services	241	83
Other fees and services	120	49
Total	$987	$568

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jan. 07, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount					$10,000,000
Debt instrument, interest rate, stated percentage		8.35%
Debt default long term debt percentage		13.35%
Debt Instrument, Maturity Date		1-Dec-18
Debt instrument, fee amount		50,000
Debt consulting placement fee		100,000
Debt related commitment fees and debt issuance costs		231,000
Debt instrument unamortized discount		283,000	281,000	400,000
Warrants to purchase common stock	298	298
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.60	$0.50	$1.60
Debt instrument Cash Maintenance	2,500,000
Repayments of Debt	5,000,000
Additions To Debt Instrument Unamortized Discount		33,000
Debt Instrument, Periodic Payment		260,000
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$1.60
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50	$0.50
Warrant
Debt Instrument [Line Items]
Warrants to purchase common stock		298
Class of Warrant or Right, Exercise Price of Warrants or Rights		$1.60
Warrants, expiry date		27-Dec-20
After December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage		1.00%
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid		$795,000
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage		2.00%

Summary_of_Debt_Detail

Summary of Debt (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt
Beginning of period	$10,000
Principal payments	0
Classification	0
End of period	10,000
Debt Discount
Beginning of period	281		400
Additions	33
Amortization expense	31
End of period	283		400
Debt, net	7,348	7,961
Long-term Debt [Member]
Debt
Beginning of period	8,242
Principal payments	0
Classification	-611
End of period	7,631
Debt Discount
Beginning of period	-281
Additions	-33
Amortization expense	31
End of period	-283
Debt, net	7,348
Short-term Debt [Member]
Debt
Beginning of period	1,758
Principal payments	0
Classification	611
End of period	2,369
Debt Discount
Beginning of period	0
Additions	0
Amortization expense	0
End of period	0
Debt, net	$2,369

Interest_Expense_Detail

Interest Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Interest expense:
Secured Promissory notes	$260	$254
Debt discount	31	30
Debt issue costs	17	17
Total interest expense	$308	$301

LongTerm_Debt_Detail

Long-Term Debt (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
2015	$1,758
2016	2,522
2017	2,741
2018	2,979
Total	$10,000	$10,000

Equity_Financing_Additional_In

Equity Financing - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Apr. 18, 2013	Mar. 31, 2015
Equity Financing [Line Items]
Proceeds from sale of common stock	$13	$7.90

Common_Stock_Warrant_Activity_

Common Stock Warrant Activity (Detail) (Warrant, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant
Number of Shares
Number of Options Outstanding, beginning	298,000	2,154,000
Issued	0	0
Exercised	0	0
Expired	0	0
Number of Options Outstanding, ending	298,000	2,154,000
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$1.60	$3.15
Issued	$0	$0
Exercised	$0	$0
Expired	$0	$0
Weighted Average Exercise Price, ending	$0.50	$3.15

Common_Stock_Warrants_Addition

Common Stock Warrants - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Jan. 07, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	298	298
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50	$1.60	$1.60
Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50	$0.50
Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.60
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	298
Common stock Warrant expiration date	27-Dec-20
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.60

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended	2 Months Ended	3 Months Ended		12 Months Ended	8 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2014	1-May-14	Jun. 30, 2014	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Jan. 02, 2015	Jan. 02, 2015
Employee Benefit Plans Disclosure [Line Items]
Restricted Stock Units Sale Price	0.01
Deferred Compensation Arrangement with Individual, Recorded Liability									22,000	22,000
Stock options
Employee Benefit Plans Disclosure [Line Items]
Withholding tax obligations		36,000
Shares withheld upon elections made to exchange RSUs		18,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	31,000
Option Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		24,000
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings		13,000
2005 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Shares withheld upon elections made to exchange RSUs			330,000
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations			500,000
Number of vested shares distributed to holders			500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014.
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	1,650,000
2014 Restricted Stock Unit Award Plan [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				37,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					50.00%	25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description				stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$26,000
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									129,000
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution									18,000
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									30,000
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									99,000
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										51,500
Share-based Compensation Arrangement by Share-based Payment Award, Description										stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	25%

Recognition_of_ShareBased_Comp

Recognition of Share-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and Development Expense, Total	$964	$1,438
Share Based Compensation Expense Recognized In Operations	160	198
Subtotal [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Expense Recognized In Operations	121	141
Research and Development Expense [Member] | Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and Development Expense, Total	39	57
General and Administrative Expense [Member] | Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	98	141
General and Administrative Expense [Member] | Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	$23	$0

Stock_Option_Award_Activity_De

Stock Option Award Activity (Detail) (Stock Option Plan, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Option Plan
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	4,556	3,738
Number of Options, Granted	0	0
Number of Options, Exercised	0	-31
Number of Options, Forfeited or expired	-75	0
Number of Options Outstanding, ending	4,481	3,707
Number of Options exercisable	3,573	3,189
Weighted Average Exercise Price, beginning	$4.14	$4.99
Weighted Average Exercise Price, Granted	$0	$0
Weighted Average Exercise Price, Exercised	$0	$1.30
Weighted Average Exercise Price, Forfeited or expired	$5.25	$0
Weighted Average Exercise Price, ending	$4.13	$5.02
Weighted Average Exercise Price, Options exercisable	$5	$5.54

Summary_of_RSU_Plan_Detail

Summary of RSU Plan (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Restricted Stock Units
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	147	829
Granted	206	0
Distributed	-129	-829
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	224	0
Vested Restricted Stock Units (RSUs)
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	147	829
Granted	0	0
Distributed	-129	-829
Vested	52	0
Forfeited or expired	0	0
Outstanding, ending	70	0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Mar. 31, 2015
Income Tax Disclosure [Line Items]
Federal income tax benefits	$51.50
Federal NOLs	151.4
U.S. statutory tax rate	34.00%
State income tax benefits	2.9
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	1.1
Research and development expiration period		which expire in the years 2024 through 2034
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$0.30
Research and development expiration period		which expire in the years 2015 through 2017
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year		2034
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year		2016

EARNINGS_PER_SHARE_EPS_Additio

EARNINGS PER SHARE ("EPS") - Additional Information (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	3,580	5,861

Reconciliation_of_Numerators_a

Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
EPS - basic
Numerator: net income (loss)	$1,239	($4,088)
Denominator:
Common shares	48,947	48,842
Vested RSUs	18	0
Basic weighted average shares outstanding	48,965	48,842
EPS - basic	$0.03	($0.08)
EPS - assuming dilution
Numerator: net income (loss)	$1,239	($4,088)
Denominator:
Common shares	48,947	48,842
Vested RSUs	170	0
Stock options	167	0
Common stock warrants	63	0
Diluted weighted average shares outstanding	49,347	48,842
EPS - diluted	$0.03	($0.08)
Common shares issuable:
Total excluded common shares	3,580	5,861
Stock options
Common shares issuable:
Total excluded common shares	3,580	3,707
Common stock warrants
Common shares issuable:
Total excluded common shares	0	2,154

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	150
Number of lawsuits served	50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint	400
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space	25
Lease expiring date	31-Mar-16